All News
Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” https://t.co/hFejdS4sjk
Dr. John Cush RheumNow ( View Tweet)
APP Pearls “Ensure a patient understands the weekly dosing instructions for methotrexate” - Ben Smith, DMSc, PA-C
Dr. John Cush RheumNow ( View Tweet)
Comprehensive review of the management of knee osteoarthritis - topicals, analgesics, narcotics, intraarticular, metabolic, nutraceuticals, TENS, acupuncture and biologics. https://t.co/3UjPQeZut9 https://t.co/z0dzENSbtX
Dr. John Cush RheumNow ( View Tweet)
Inflammatory vs. Noninflammatory Pain
https://t.co/ZZLMnT8IVO https://t.co/W0tVK75raN
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Glossary for Giant Cell Arteritis
Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving https://t.co/yfJXZx5r6G
Dr. John Cush RheumNow ( View Tweet)
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/Q0TKznTWdV
Dr. John Cush RheumNow ( View Tweet)
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/Yg7DBOTW8o
Dr. John Cush RheumNow ( View Tweet)
JAMA -- Full read review "Uveitis in Adults:"
- affects adults 20 to 50 years
- noninfectious anterior uveitis: corticosteroids 1st line Rx
- posterior noninfectious uveitis: DMARDs 1st line Rx; Biologics 2nd line
https://t.co/BJQkPtK2z2 https://t.co/0puqX5iieE
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Vitamin D for Prevention of Disease
JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults.
https://t.co/PFHO7x5nxH https://t.co/fvwzLgYGJe
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?
Recent large-scale clinical trials have broadened therapeutic options for SARD-ILD beyond immunosuppressants, offering new hope for patients with these serious conditions.
https://t.co/RLlOdEWTOa https://t.co/UI9cdJ5Ovd
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025
https://t.co/yzQVt1fLKW https://t.co/hrbEeppZhW
Links:
Dr. John Cush RheumNow ( View Tweet)
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Methotrexate intolerance in rheumatoid arthritis
Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week. https://t.co/hzfF7UVKVI
Dr. John Cush RheumNow ( View Tweet)
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis
The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/KacbtcMn5G
Dr. John Cush RheumNow ( View Tweet)
Algorithm for the treatment of calcinosis #calcinosis #ACR24 https://t.co/NZhP7Enzrp https://t.co/I0HLtYjzgb
Links:
Dr. John Cush RheumNow ( View Tweet)
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/PTJPhcvnzC
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Overview of the VEXAS Syndrome
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
https://t.co/O3BoOElcbT https://t.co/0hSEWqMFVf
Dr. John Cush RheumNow ( View Tweet)
Inflammatory vs. Noninflammatory Pain
https://t.co/ZZLMnT8IVO https://t.co/dnZHqV1jcK
Dr. John Cush RheumNow ( View Tweet)
Intro to ILD (Part I): the essentials
🫁 Definition & basics
🔬 Key pathology patterns
🧑⚕️ Clinical approach
📋 What rheums need to know
⬇️ Download & learn more: https://t.co/Fn76PiGsPl
Created by
@MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/JpyE3T7Atj
Dr. John Cush RheumNow ( View Tweet)
Is the term polymyositis obsolete?.. now being replaced by dermatomyositis, necrotizing myopathy, inclusion body myositis, antisynthetase syndrome & overlap myositis. Full read overview of inflammatory myositis & new treatments from Joint Bone & Spine https://t.co/X46sptp1Ax https://t.co/M80026Z3Ur
Links:
Dr. John Cush RheumNow ( View Tweet)
